Results 41 to 50 of about 3,049 (238)
Parametric Linear Dynamic Logic [PDF]
EPTCS 161, 2014, pp. 60-73, 2014 We introduce Parametric Linear Dynamic Logic (PLDL), which extends Linear Dynamic Logic (LDL) by temporal operators equipped with parameters that bound their scope. LDL was proposed as an extension of Linear Temporal Logic (LTL) that is able to express all $\omega$-regular specifications while still maintaining many of LTL's desirable properties like ...
arxiv +1 more source
CPT: Pharmacometrics &Systems Pharmacology, EarlyView.ABSTRACT Evinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH). A population pharmacokinetic (PK)/pharmacodynamic (PD) model was previously developed to characterize ...
Sébastien Bihorel +8 more
wiley +1 more source
International Journal of Vascular Medicine, 2016 Objective. To investigate vascular endothelial function (VEF) responses to a single low-density lipoprotein (LDL) apheresis session in hypercholesterolemic patients undergoing chronic treatment. Methods. We measured brachial artery flow-mediated dilation
Kevin D. Ballard +7 more
doaj +1 more source
Lipids in Health and Disease, 2018 Background Preeclampsia is a life-threatening disease in pregnancy, and its complex pathomechanisms are poorly understood. In preeclampsia, lipid metabolism is substantially altered.
Christine Contini +11 more
doaj +1 more source
Rethinking Soft Label in Label Distribution Learning Perspective [PDF]
arXiv, 2023 The primary goal of training in early convolutional neural networks (CNN) is the higher generalization performance of the model. However, as the expected calibration error (ECE), which quantifies the explanatory power of model inference, was recently introduced, research on training models that can be explained is in progress.
arxiv
CPT: Pharmacometrics &Systems Pharmacology, EarlyView.ABSTRACT Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH.
Sébastien Bihorel +18 more
wiley +1 more source
Is LDL apheresis a thing of the past?
South African General Practitioner, 2020 Patients with severe hypercholesterolaemia have a high lifetime risk for developing cardiovascular disease. These patients are traditionally treated with high-intensity statins and ezetimibe. Some patients are refractory to treatment and cannot achieve a desirable reduction in low-density lipoprotein cholesterol (LDL-C).
M Vally, R Khan, A Orchard
openaire +2 more sources
American Journal of Perinatology Reports, 2012 Pregnancy in women with homozygous familial hypercholesterolemia (FH) has been rarely reported and might pose risks on the mother and her fetus. Although most reported cases remained on low-density lipoprotein (LDL) apheresis, there are no clear ...
Akl C. Fahed, Anwar H. Nassar
doaj +1 more source
Inaccurate Label Distribution Learning [PDF]
arXiv, 2023 Label distribution learning (LDL) trains a model to predict the relevance of a set of labels (called label distribution (LD)) to an instance. The previous LDL methods all assumed the LDs of the training instances are accurate. However, annotating highly accurate LDs for training instances is time-consuming and very expensive, and in reality the ...
arxiv
Rheocarna treatment for non‐dialysis patients
Therapeutic Apheresis and Dialysis, EarlyView.Abstract Introduction Rheocarna has attracted attention as an alternative therapy for severe chronic limb‐threatening ischemia, and there have been reports of its usefulness. However, most of these reports have been on dialysis patients, and there are few reports on the treatment conditions and efficacy in non‐dialysis patients.
Atsushi Ohkubo +11 more
wiley +1 more source